Omeros Dividends and Buybacks
Dividend criteria checks 0/6
Omeros does not have a record of paying a dividend.
Key information
n/a
Dividend yield
4.7%
Buyback Yield
| Total Shareholder Yield | 4.7% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Omeros Q3 2024 - Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns
Nov 17Omeros: Troubled Company Working Its Way Out Of The Morass
Jul 19Omeros: Still Worth A Look Despite Narsoplimab Woes
Feb 14Is Omeros (NASDAQ:OMER) A Risky Investment?
Jul 26
Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt
Mar 17Omeros: Taking It To The Max
Oct 05Omeros falls 11% after reporting clinical data for COVID-19 therapy
Sep 15Omeros: Managing An Investment After A Winning Trade
Aug 16Omeros granted FDA’s Orphan Drug designation for PNH candidate
Jul 28Omeros: Follow The Bouncing Ball
Jul 04Omeros: On Death's Door
Jun 02Omeros: The Weight Of The Wait, A Conundrum
May 03Omeros: Despite Its Promise, The CRL Is A Huge Obstacle
Feb 21Omeros: A New Year Beckons
Dec 06Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates
Dec 04Omeros: What's Left
Oct 15Omeros: The Prize Is Nigh (Again)
Sep 14Omeros: PDUFA Delay Presents An Opportunity
Jul 03Omeros posts preliminary results from early-stage OMS906 trial
Jun 09Should Shareholders Reconsider Omeros Corporation's (NASDAQ:OMER) CEO Compensation Package?
Jun 05Omeros posts preliminary results from COVID-19 patients treated with narsoplimab
May 28CDC and CMS OKs Omeros' ICD-10 codes for HSCT-TMA diagnosis and narsoplimab
May 04Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if OMER's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OMER's dividend payments have been increasing.
Dividend Yield vs Market
| Omeros Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (OMER) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.3% |
| Industry Average (Pharmaceuticals) | 2.5% |
| Analyst forecast (OMER) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate OMER's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OMER's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate OMER's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OMER has not reported any payouts.